MX2019015150A - Composiciones antagonistas de nk-1 y métodos para su uso en el tratamiento de la depresión. - Google Patents

Composiciones antagonistas de nk-1 y métodos para su uso en el tratamiento de la depresión.

Info

Publication number
MX2019015150A
MX2019015150A MX2019015150A MX2019015150A MX2019015150A MX 2019015150 A MX2019015150 A MX 2019015150A MX 2019015150 A MX2019015150 A MX 2019015150A MX 2019015150 A MX2019015150 A MX 2019015150A MX 2019015150 A MX2019015150 A MX 2019015150A
Authority
MX
Mexico
Prior art keywords
methods
treating depression
antagonist compositions
antagonist
treating
Prior art date
Application number
MX2019015150A
Other languages
English (en)
Inventor
Thomas N Chase
Kathleen E Clarence-Smith
Original Assignee
Chase Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chase Therapeutics Corp filed Critical Chase Therapeutics Corp
Publication of MX2019015150A publication Critical patent/MX2019015150A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención describe la combinación de un antagonista de NK1 con pramipexol o una sal o solvato farmacéuticamente aceptable del mismo, útil para tratar trastornos depresivos, incluido el trastorno depresivo mayor.
MX2019015150A 2017-06-30 2018-06-28 Composiciones antagonistas de nk-1 y métodos para su uso en el tratamiento de la depresión. MX2019015150A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762527215P 2017-06-30 2017-06-30
PCT/US2018/039883 WO2019006050A1 (en) 2017-06-30 2018-06-28 NK-1 ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN TREATING DEPRESSION

Publications (1)

Publication Number Publication Date
MX2019015150A true MX2019015150A (es) 2020-08-13

Family

ID=64742221

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015150A MX2019015150A (es) 2017-06-30 2018-06-28 Composiciones antagonistas de nk-1 y métodos para su uso en el tratamiento de la depresión.

Country Status (14)

Country Link
US (3) US11266633B2 (es)
EP (1) EP3645120A4 (es)
JP (1) JP7158425B2 (es)
KR (1) KR20200026920A (es)
CN (1) CN111032158A (es)
AU (1) AU2018290889A1 (es)
BR (1) BR112019028034A2 (es)
CA (1) CA3104811A1 (es)
EA (1) EA202090180A1 (es)
IL (1) IL271464B1 (es)
MA (1) MA49524A (es)
MX (1) MX2019015150A (es)
TW (1) TWI826380B (es)
WO (1) WO2019006050A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018251604B2 (en) 2017-04-10 2022-04-14 Chase Therapeutics Corporation NK1-antagonist combination and method for treating synucleinopathies
EP3645120A4 (en) * 2017-06-30 2021-03-24 Chase Pharmaceuticals Corporation NK-1 ANTAGONIST COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DEPRESSION
US20230338355A1 (en) * 2020-07-30 2023-10-26 Acer Therapeutics Inc. Nk antagonists for contraception
WO2023220224A1 (en) * 2022-05-12 2023-11-16 St. Jude Children's Research Hospital, Inc. Synergistic antifungal composition and method

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE45735T1 (de) 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
KR100214905B1 (ko) 1991-05-31 1999-08-02 디. 제이. 우드, 스피겔 알렌 제이 퀴누클리딘 유도체
US5719147A (en) 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
DE4241013A1 (de) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
IL111002A (en) 1993-09-22 1998-09-24 Glaxo Group Ltd History of piperidine, their preparation and the pharmaceutical preparations containing them
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
JP2001502311A (ja) 1996-10-07 2001-02-20 メルク シヤープ エンド ドーム リミテツド 抗鬱及び／又は抗不安薬としてのｃｎｓ浸透性ｎｋ―１受容体拮抗薬
ES2234039T3 (es) 1996-12-02 2005-06-16 MERCK SHARP & DOHME LTD. Uso de antagonistas del receptor nk-1 para tratar trastornos de depresion mayor.
US6271230B1 (en) * 1997-12-01 2001-08-07 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating cognitive disorders
DE19830201A1 (de) 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
CA2301899C (en) 1998-07-27 2008-11-18 Boehringer Ingelheim Pharma Kg Agent with an antidepressant activity
DK1394150T3 (da) 1999-02-24 2011-03-21 Hoffmann La Roche 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
KR100501608B1 (ko) 2000-07-14 2005-07-18 에프. 호프만-라 로슈 아게 4-페닐-피리딘 유도체의 ｎｋ1 수용체의 길항성선구약물로서의 ｎ-산화물
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US6620438B2 (en) * 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
ES2272408T3 (es) 2000-12-14 2007-05-01 F. Hoffmann-La Roche Ag Matriz lipidica autoemulsificante (selm).
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
TWI341198B (en) 2004-01-27 2011-05-01 Merck Sharp & Dohme Hydroisoindoline tachykinin receptor antagonists
CA2554346C (en) 2004-01-30 2009-11-17 Pfizer Products Inc. Parenteral formulations comprising a beta-cyclodextrin and a preservative
BRPI0508254A (pt) 2004-03-02 2007-07-24 Pharmacia Corp métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
AU2006269383A1 (en) 2005-07-11 2007-01-18 Merck Sharp & Dohme Corp. Process for making hydroisoindoline tachykinin receptor antagonists
US20070225279A1 (en) 2006-03-24 2007-09-27 Wyeth Therapeutic combinations for the treatment of depression
EP2129381A1 (en) 2007-01-24 2009-12-09 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
US20080254117A1 (en) 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
GB0806652D0 (en) 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
CN105503870A (zh) 2009-08-14 2016-04-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂
MX345236B (es) 2009-09-18 2017-01-23 Chase Pharmaceuticals Corp Metodo y composicion para tratar la demencia de tipo alzheimer.
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
WO2012140604A1 (en) 2011-04-15 2012-10-18 Sandoz Ag Stable formulations of pramipexole hydrochloride
WO2012175434A1 (en) 2011-06-20 2012-12-27 Glaxo Group Limited Pharmaceutical formulations comprising vestipitant
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
JOP20130213B1 (ar) 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
AU2013343105B2 (en) 2012-11-08 2016-04-14 Pfizer Inc. Heteroaromatic compounds as dopamine D1 ligands
JP2016532660A (ja) 2013-10-08 2016-10-20 イノファーマ インク アプレピタント経口液体製剤
EP3193830B1 (en) 2014-09-19 2023-11-01 Heron Therapeutics, Inc. Emulson formulations of aprepitant
ES2939296T3 (es) 2014-12-23 2023-04-20 Avalo Therapeutics Inc Compuestos, composiciones y métodos
CN107531674B (zh) 2015-02-11 2020-07-31 赛诺维信制药公司 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物
KR102623321B1 (ko) * 2015-02-11 2024-01-09 선오비온 파마슈티컬스 인코포레이티드 중추 신경계 질환을 치료하기 위한 융합된 다이하이드로-4h-피라졸로[5,1-c][1,4]옥사진일 화합물 및 유사체
US9850267B2 (en) 2015-06-03 2017-12-26 Navinta, Llc Crystalline fosaprepitant dicyclohexylamine salt and its preparation
AU2016323977B9 (en) * 2015-09-16 2021-03-04 The Trustees Of Columbia University In The City Of New York Carboxylic diarylthiazepineamines as mu-opioid receptor agonists
US10005803B2 (en) 2015-10-06 2018-06-26 Helsinn Healthcare Sa Crystalline forms of fosnetupitant
NL2015865B1 (en) 2015-11-27 2017-06-13 Le Vet B V Maropitant Formulation.
KR102623819B1 (ko) 2017-03-27 2024-01-10 체이스 테라퓨틱스 코포레이션 시누클레인병변을 치료하기 위한 조성물 및 방법
AU2018251604B2 (en) * 2017-04-10 2022-04-14 Chase Therapeutics Corporation NK1-antagonist combination and method for treating synucleinopathies
EP3645120A4 (en) * 2017-06-30 2021-03-24 Chase Pharmaceuticals Corporation NK-1 ANTAGONIST COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DEPRESSION

Also Published As

Publication number Publication date
IL271464B1 (en) 2024-04-01
US11813248B2 (en) 2023-11-14
US20200147053A1 (en) 2020-05-14
TW201906604A (zh) 2019-02-16
AU2018290889A1 (en) 2020-02-13
WO2019006050A1 (en) 2019-01-03
US11266633B2 (en) 2022-03-08
US20220160683A1 (en) 2022-05-26
US11813247B2 (en) 2023-11-14
CA3104811A1 (en) 2019-01-03
EP3645120A4 (en) 2021-03-24
JP7158425B2 (ja) 2022-10-21
JP2020526494A (ja) 2020-08-31
KR20200026920A (ko) 2020-03-11
MA49524A (fr) 2021-05-26
BR112019028034A2 (pt) 2020-07-07
TWI826380B (zh) 2023-12-21
EA202090180A1 (ru) 2020-05-26
EP3645120A1 (en) 2020-05-06
US20220168281A1 (en) 2022-06-02
CN111032158A (zh) 2020-04-17
IL271464A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
IL282487A (en) TYK2 inhibitors and their use
EA201890318A1 (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2019015150A (es) Composiciones antagonistas de nk-1 y métodos para su uso en el tratamiento de la depresión.
MX2019001043A (es) Metodos y composiciones para el tratamiento de la mielofibrosis.
MX2017014192A (es) Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.
MX2017011206A (es) Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer.
IL282090A (en) tyk2 inhibitors and uses thereof
IL283409A (en) tyk2 inhibitors and uses thereof
SG11202100818RA (en) Tlr7/8 antagonists and uses thereof
MY186271A (en) Ophthalmic compositions and methods of use therefor
ZA202101362B (en) Compositions and methods for treating the eye
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
ZA202101342B (en) Compositions and methods for treating the eye
MX2020011668A (es) Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.
MX2020012979A (es) Métodos para aumentar la exposición al plasma de sepiapterina.
IL275985A (en) Preparations and methods for the treatment of retinal disorders
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
MX2019014024A (es) Tratamiento de los trastornos depresivos.
NZ733451A (en) Combination therapy for pulmonary hypertension
ZA202101361B (en) Compositions and methods for treating the eye
ZA202101360B (en) Compositions and methods for treating the eye
WO2018094106A3 (en) ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
ZA202007183B (en) Compositions and methods for treating the eye